Overview
PET MRI integrates metabolic PET data with high soft tissue contrast MRI to improve lesion characterization and staging. The hybrid modality reduces radiation compared with PET CT for some indications and offers simultaneous multiparametric assessment. Clinical workflows require coordinated protocols and scheduling.
Clinical Applications
PET MRI is valuable in neuro oncology for tumor delineation and in pediatric oncology to reduce radiation exposure. It supports cardiac sarcoidosis assessment and whole body oncologic staging in select cases. Multiparametric MRI sequences add functional and structural context to PET findings.
Operational Considerations
Hybrid scanners require synchronized acquisition protocols and expertise in both PET and MRI physics and safety. Attenuation correction methods and motion correction are technical challenges that affect quantification. Scheduling and throughput considerations influence cost effectiveness and utilization.
Future Directions
Advances in tracer development and quantitative PET MRI biomarkers may expand clinical indications and research applications. Integration with AI for image fusion and automated quantification will streamline interpretation. Comparative effectiveness studies will clarify optimal use cases and reimbursement pathways.